1932

Abstract

The first integrase inhibitor licensed to treat HIV-1 infection was approved in late 2007, more than a decade after the introduction of the first inhibitors of the HIV-1 reverse transcriptase and protease. The unique biochemical and molecular mechanism of action of this novel class of antiretroviral drugs is the fundamental basis for their activity in treating multidrug-resistant HIV-1 infection and is important for understanding both the cellular and in vivo pharmacology and metabolism of these agents. In addition, available pharmacokinetic and drug interaction data for raltegravir and elvitegravir, the two integrase inhibitors that are the most advanced in clinical development to date, are reviewed.

Keyword(s): AIDSantiretroviralsHIVintegrase
Loading

Article metrics loading...

/content/journals/10.1146/annurev.pharmtox.011008.145553
2009-02-10
2024-04-15
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.pharmtox.011008.145553
Loading
/content/journals/10.1146/annurev.pharmtox.011008.145553
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error